As of 2025-03-16, the Relative Valuation of VistaGen Therapeutics Inc (VTGN) is (44.26) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.72 USD, the upside of VistaGen Therapeutics Inc based on Relative Valuation is -1727.0%.
The range of the Relative Valuation is (35.63) - (50.12) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.7x - 36.3x | 29.0x |
| Forward P/E multiples | 19.4x - 30.6x | 25.0x |
| Fair Price | (35.63) - (50.12) | (44.26) |
| Upside | -1410.1% - -1942.8% | -1727.0% |
| Date | P/E |
| 2025-03-13 | -1.71 |
| 2025-03-12 | -1.70 |
| 2025-03-11 | -1.66 |
| 2025-03-10 | -1.62 |
| 2025-03-07 | -1.68 |
| 2025-03-06 | -1.63 |
| 2025-03-05 | -1.65 |
| 2025-03-04 | -1.62 |
| 2025-03-03 | -1.52 |
| 2025-02-28 | -1.65 |
| 2025-02-27 | -1.55 |
| 2025-02-26 | -1.59 |
| 2025-02-25 | -1.60 |
| 2025-02-24 | -1.66 |
| 2025-02-21 | -1.79 |
| 2025-02-20 | -1.75 |
| 2025-02-19 | -1.74 |
| 2025-02-18 | -1.79 |
| 2025-02-14 | -1.81 |
| 2025-02-13 | -1.74 |
| 2025-02-12 | -1.67 |
| 2025-02-11 | -1.65 |
| 2025-02-10 | -1.68 |
| 2025-02-07 | -1.71 |
| 2025-02-06 | -1.75 |
| 2025-02-05 | -1.80 |
| 2025-02-04 | -1.74 |
| 2025-02-03 | -1.78 |
| 2025-01-31 | -1.76 |
| 2025-01-30 | -1.79 |
| 2025-01-29 | -1.74 |
| 2025-01-28 | -1.74 |
| 2025-01-27 | -1.76 |
| 2025-01-24 | -1.80 |
| 2025-01-23 | -1.81 |
| 2025-01-22 | -1.82 |
| 2025-01-21 | -1.84 |
| 2025-01-17 | -1.78 |
| 2025-01-16 | -1.78 |
| 2025-01-15 | -1.81 |
| 2025-01-14 | -1.73 |
| 2025-01-13 | -1.79 |
| 2025-01-10 | -1.81 |
| 2025-01-08 | -1.85 |
| 2025-01-07 | -1.90 |
| 2025-01-06 | -1.95 |
| 2025-01-03 | -2.04 |
| 2025-01-02 | -2.02 |
| 2024-12-31 | -1.80 |
| 2024-12-30 | -1.71 |